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The insulin receptor is an integral glycoprotein of the plasma membrane in most mammalian
cells. The gene encodes a 190 kDa proreceptor that undergoes a number ofprocessing steps. The
gene is constitutively expressed, but at least one form of regulation has been demonstrated.
Glucocorticoids increase the number of insulin receptors on the surface of cultured human
lymphocytes, a process which is accompanied by an increase in transcription ofthegene. N-linked
glycosylation and amide-linked acylation occur as co-translational events. Subsequently, the
proreceptor is cleaved into alpha and beta subunits; the subunits then undergo an ester-linked
acylation step and N-linked complex glycosylation. In addition, 0-linked glycosylation has been
recently described in the beta subunit. The mature insulin receptor is inserted into the plasma
membrane as an alpha2-beta2 disulfide-linked heterodimer. The receptor can be further regulated
on the cell surface by insulin binding and receptor-mediated endocytosis. The receptor concentra-
tion on the cell surface then becomes a function of the internalization rate and the receptor
recycling rate. Receptor regulation is a relevant feature of many forms of clinical insulin
resistance, and recently genetic mutations have been described that determine both the binding
properties ofthe receptor and its translocation and processing properties.
INTRODUCTION
The insulin receptor is a cell surface integral membrane protein present in most
mammalian cells. The receptor recognizes and binds insulin; the strength ofthe insulin
signal transduced is a function of the concentration of the insulin receptor complex.
Thus, the concentration of insulin, of the receptor, or both, may be varied to regulate
the magnitude ofthe insulin signal.
Early studies employing biochemical techniques defined the insulin receptor as a
specific protein and defined its steady state binding parameters. More recent studies
employing cell biologic techniques have defined mechanisms of regulation, and
molecular genetic studies have elucidated the structure and sequence of the receptor,
permitting description ofspecific functional domains. Clinical studies have utilized all
of these techniques to describe the relevance of the insulin receptor to a number of
diabetic syndromes.
STRUCTURE OF THE MATURE INSULIN RECEPTOR
The mature receptor that is inserted into the plasma membrane consists ofan alpha
subunit that contains the insulin-binding domain and a beta subunit that contains a
tyrosine kinase domain (Fig. 1). The insulin receptor is composed of a dimer of two
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FIG. 1. Structure of the
CYlOPLASM insulin receptor on the cell
surface.
alpha and two beta subunits linked by disulfide bonds. Insulin binds to the alpha
subunit and activates autophosphorylation of the beta subunit. Once phosphorylated,
the beta subunit is an activated tyrosine kinase. The details of other forms of
phosphorylation of the insulin receptor and subsequently of its substrates are not well
understood. [1]. It seems clear, however, that the binding of insulin and receptor
autophosphorylation are necessary, if not sufficient, events to trigger insulin action. It
is possible that reagents other than insulin, such as insulinomimetic immunoglobulins,
may be able to circumvent part of this pathway (2].
BIOSYNTHESIS OF THE RECEPTOR-THE GENE AND cDNA
The insulin receptor gene is located on chromosome 19, estimated to be greater than
120 kB, and contains 22 exons [3]. Several groups have identified the 5' flanking region
which is noteworthy for the absence of "TATA" and "CAAT" box sequences
[3,4,5,6]. There are, however, multiple G-C rich regions that may be possible Spl
binding sites, consistent with the promoter sequence for many constitutively expressed
"housekeeping" genes. By primer extension analysis, many transcriptional initiation
sites have been identified in the 5' untranslated region. Transcription is induced by
glucocorticoids, but no specific glucocorticoid regulatory sequence has been identified
[7,8].
The human insulin receptor cDNA (approximately 5 kB) encodes a single chain
proreceptor [9,10], which was previously described by biosynthetic labeling studies
[II] (Fig. 2). It is interesting that insulin is also synthesized by way of a single chain
precursor [12]. The alpha subunit contains a cysteine-rich region, consistent with the
ligand-binding domain. There is also a sequence, with four basic amino acids
separating the alpha and beta subunits, which is the site of proteolytic cleavage. The
beta subunit has been intensely examined by site-directed mutagenesis to determine
necessary functional domains. Of interest are the extracellular, transmembrane,
tyrosine kinase, and carboxy terminal regions. Superimposed on this protein backbone
are a number ofprocessing events.
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FIG. 2. Schematic representation of the human insulin receptor cDNA. The region of the cDNA
designated ArgLysArgArg represents the cleavage site between the a- and ,B-subunits. The Lys 1018 of the
fl-subunit is the adenosine triphosphate binding site. The region designated Tyr 1146, 1150, and 1151
represents the biologically significant substrates for receptor phosphorylation. Tyr 960, 1316, and 1322
represent phosphorylation sites ofuncertain significance.
For the most part, the insulin receptor gene is transcribed in a constitutive fashion,
and the concentration of mRNA is directly proportional to the number of receptors on
the cell surface [13]. Aside from developmental regulation, and regulation based on
cell transformation, the only known positive regulators of insulin receptor gene
expression are glucocorticoids [7,8]. In a time- and dose-related fashion, glucocorti-
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FIG. 3. Effect ofhydrocortisone on insulin receptor mRNA. Cytoplasmic mRNA from IM-9 lymphocytes
was hybridized to insulin receptor and ferritin anti-sense riboprobes and identified by SI endonuclease
protection assay. The levels of receptor and ferritin message in cells exposed to increasing concentrations
(dose-response A = 0 hydrocortisone, B = 10 nm, C = 50 nm, D = 80 nm, E = 200 nm, and F = 1.4 ,um)
and longer duration (time course measured in hours) of hydrocortisone are shown. For details of these
experiments, see [7].
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coids increase the number of insulin receptors on the surface of cultured human
lymphocytes. This process is related tothe synthetic pathway, inasmuch as the receptor
turnover rate is not affected. Receptor mRNA levels are proportionally increased, and
this increase is a direct transcriptional effect (Fig. 3). While insulin itselfwill increase
proreceptor synthesis to some extent, this increase is not accompanied by an increase in
gene transcription [7].
BIOSYNTHESIS-RECEPTOR TRANSLATION
The translation ofthe insulin receptor message presumably occurs by the same route
as other integral membrane proteins, i.e., on membrane-bound ribosomes (Fig. 4). The
message encodes a 190 kDa proreceptor protein which undergoes two recognized
co-translational events: (a) N-linked glycosylation ofthe high mannose type and (b) an
amide-linked acylation step. There are 18 potential glycosylation sites on the prorecep-
tor, with 14 on the alpha subunit and four on the extracellular domain of the beta
subunit. It is noted that there are 15 potential glycosylation sites on the alpha subunit
[9,10], but one of these is composed of asn-pro-ser, which is very unlikely to be
glycosylated [14]. As with other proteins, a Glc3Man9GlcNac2 oligosaccharide is
transferred to an asparagine ofthe protein via a dolichol phosphate intermediate. This
oligosaccharide chain is processed to a complex type ofchain by removal of the three
glucoses and several mannoses prior to addition of other monosaccharides and sialic
acid. If removal of the glucoses is inhibited, the receptor concentration on the cell
surface is reduced, suggesting that processing to complex chains is necessary for
correct targeting of the receptor to the cell surface [15,16]. Further processing of the
high mannose chains to complex chains occurs in the Golgi.
The insulin receptor also contains covalently linked fatty acids. In biosynthetic
labeling studies, radiolabeled myristate and palmitate are found attached to the insulin
receptor. One of these fatty acids appears to be attached very early, in an amide
linkage, as inhibition ofprotein synthesis prevents its occurrence [17].
As soon as the protein chain is synthesized, possibly as a co-translational event,
interchain disulfide dimerization occurs (Fig. 5). Thus, the newly synthesized prore-
ceptor is a disulfide-linked dimer which has undergone high mannoseglycosylation and
amide-linked acylation. The newly synthesized proreceptor binds insulin but with
reduced affinity. The tyrosine kinase activity of the proreceptor is reduced in
proportion to the reduced binding affinity (Fig. 6). Thus, the proreceptor, like
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proinsulin, is fully active but with diminished affinity as compared to the mature
peptide.
PROCESSING OF THE PRORECEPTOR
Further processing of the proreceptor presumably occurs in the Golgi apparatus.
Cleavage ofthe proreceptor to produce thepre-alpha and pre-beta subunits occurs very
early, but probably in the Golgi. The mature alpha subunit has an apparent molecular
weight of 135 kDa and the mature beta subunit, one of 95 kDa. The insulin receptor
contains both high mannose and complex type of N-linked oligosaccharides since the
mature receptor contains endoglycosidase-sensitive carbohydrates [18]. The difference
in molecular weight of the alpha and beta subunits from that predicted by the amino
acid sequence is largely attributed to N-linked glycosylation.
Two additional processing steps less well characterized probably occur in the Golgi.
In addition to the amide-linked fatty acid, there is ester linkage of fatty acids to the
insulin receptor. Both the alpha and beta subunits contain covalently bound fatty acids
[17]. The part that these fatty acids play in receptor function and processing is
unknown at the present time.
Recently, another post-translational modification of the insulin receptor has been
described, 0-linked glycosylation [19]. N-glycanase, an enzyme that specifically
removes N-linked oligosaccharides, removes all of the carbohydrate moieties from
the proreceptor and the alpha subunit, whereas, in the beta subunit, in addition to
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FIG. 6. Insulin dose-response autophosphorylation of immunoprecipitated mature insulin
receptor and proreceptor. Mature receptor and precursor from IM-9 cells were isolated by
sequential lectin chromatography and immunoprecipitation with site-specific anti-receptor
antibody. Leftpanel: Autophosphorylation response to increasing concentrations of insulin in
the (3-subunit (95 kDa) isolated by wheat germ agglutinin chromatography followed by
SDS-polyacrylamide gel electrophoresis and autoradiography. Rightpanel. The proreceptor
(190 kDa) isolated by lentil-wheat germ chromatography followed by SDS-polyacrylamide gel
electrophoresis and autoradiography. Note the attenuation in phosphorylation in the prore-
ceptor as compared to the mature fl-subunit.
N-glycanase, 0-glycanase, an enzyme that specifically removes 0-linked oligosac-
charides, is required to remove all of the carbohydrate. The 0-linked carbohydrate is
apparently limited to a single tryptic peptide fragment which also contains N-linked
carbohydrate. The significance of this newly described 0-linked glycosylation to the
function or processing of the insulin receptor is presently unknown.
THE FULLY PROCESSED RECEPTOR
Following the processing events described, the mature receptor is transferred from
the Golgi to the plasma membrane. The nature ofthis transfer process is unknown, but
it would appear the receptor is inserted into the membrane in a random fashion;
however, once inserted into the membrane, the receptor is freely mobile in the plane of
the plasma membrane. This finding is based on morphometric studies that have shown
that "'I5-insulin binds initially in a preferential fashion to the microvillus surface of the
membrane and, with time at 370C, redistributes to the non-villus surface [20]. Other
evidence for mobility comes from fluorescent microscopy and from electron micro-
scopic autoradiographic studies that have shown that the insulin receptor complex
redistributes to the Golgi pole of the cell when the temperature of initial binding is
increased to 370C. There is no evidence for an extensive intracellular pool of fully
processed receptors that can be immediately recruited to the plasma membrane, as
reported for the glucose transporter when the cell is stimulated by insulin.
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The t'/2 for receptor turnover in cultured human lymphocytes is approximately six to
eight hours [21]; this rate is augmented by insulin binding. This "down-regulation" or
ligand-induced receptor regulation was the first evidence for a process that appears
to be general for most polypeptide hormones [22]. The mechanism of this down-
regulation appears to be receptor-mediated endocytosis ofthe insulin receptor complex
[20].
RECEPTOR-MEDIATED ENDOCYTOSIS OF THE INSULIN
RECEPTOR COMPLEX
When '251-insulin, under physiologic conditions, binds to cell surface receptors on
cultured or freshly isolated cells, the hormone receptor complex is internalized.
Subsequently, a series of intracellular events ensues that can dissociate the hormone
from its receptor (Fig. 7).
A number of experimental observations suggest that internalization is the major
mechanism by which cell surface insulin receptors are "down-regulated." In cultured
human lymphocytes, receptor gene transcription is not affected by down-regulating
conditions [7]. In fact, there is a small increase in proreceptor translation under these
circumstances [23]. In other cells, there is an effect to inhibit gene transcription
analogous to the effect of internalized cholesterol in the down-regulation of the
low-density lipoprotein (LDL) receptor [24].
The structures involved in endocytosis appear to be relatively nonspecific and similar
for many other polypeptide hormones, growth factors, and other unrelated ligands.
Labeled insulin is initially localized in coated pits on thecell surface which invaginates,
fuses, and then fissions to form coated vesicles. These vesicles rapidly lose their
clatherin coat and progressively become larger non-coated structures called endo-
somes. The acidification of endosomes promotes dissociation of the ligand receptor
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complex, permitting the ligand and receptor to be processed independently [20].
Furthermore, the beta subunit ofthe receptor with its tyrosine kinase domain oriented
toward the cytoplasmic surface could potentially interact with other proteins or
structures as an activated tyrosine kinase [25].
The receptor appears to be recycled predominantly from this endosomal compart-
ment based on kinetic analysis, but morphologic data have demonstrated that the
receptor can be recycled from other vesicular structures such as lysosomes. Whether
there is some interaction of the recycling vesicles with those vesicles involved in the
transfer of newly synthesized receptors from the Golgi to the cell surface is at present
unknown. Furthermore, it is not clear how specificity is determined, inasmuch as many
different polypeptides appear to be recycled in the same or similar vesicles [20]. It is
known that certain types of receptors, such as the LDL receptor, recycle continuously,
whereas internalization and recycling of the insulin receptor predominantly requires
ligand binding. Thus, down-regulation of the receptor is primarily determined by the
rate of receptor endocytosis and the rate ofreceptor recycling.
MECHANISMS REGULATING RECEPTOR-MEDIATED ENDOCYTOSIS
The internalization of the insulin receptor occurs predominantly by way of coated
pits [20]. Whether this is an exclusive mechanism, however, is uncertain, inasmuch as
exclusivecoated-pit internalization has been shown, todate, only for the LDL receptor.
Two mechanisms have received recent attention. The first is that insulin receptors with
a mutation at the adenosine triphosphate binding site that prevents autophosphoryla-
tion are not internalized [26,27], which suggests a possible role for autophosphoryla-
tion in the endocytotic event. On the other hand, many ligand receptors such as the
growth hormone receptor [28] and the LDL receptor are not phosphorylated. Thus,
phosphorylation cannot be a general mechanism regulating endocytosis. The other
interesting question is whether the process is driven by a specific amino acid sequence
in the intracytoplasmic region of the receptor. In this regard, a consensus sequence
among several types of receptors, including the LDL receptor and the class I antigen
receptor, has been suggested [29].
RELEVANCE OF THE INSULIN RECEPTOR TO CLINICAL DISEASE
Insulin resistance is a dominant and central feature in obesity, typical type II
diabetes, and in several syndromes of extreme alternation of insulin action. Thus, the
insulin receptor has a pivotal role in the study ofinsulin resistance. In obesity and type
11diabetes, the receptor is "down-regulated." This ligand-induced regulation, presum-
ably mediated by internalization, decreases the concentration of insulin receptors on
the cell surface and, therefore, is a potential factor in clinical insulin resistance; this
condition may occur in addition to any other post-receptor defect.
In both type I and type II diabetes, receptor-mediated endocytosis of the insulin
receptor is impaired, suggesting that there may be a mechanism for maintaining
insulin receptors on the cell surface under circumstances where insulin action is
reduced [30,31,32]. Thus "down-regulation" is a feature of most hyperinsulinemic
states, whether diabetes is present or not. The impaired internalization appears to be
primarily a feature ofthehyperglycemicdiabetic state and can be reversed with insulin
therapy.
Furthermore, several genetic defects have now been elucidated that are associated
with extreme forms of insulin resistance (Table 1). In one ofthese disorders, a specific
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TABLE I
Mutations of the Insulin Receptor Gene Found in Patients with Syndromes
of Extreme Insulin Resistance
Mutationa Functional Consequence References
a-subunit Phe382 to Val Failure to translocate to the [33]
plasma membrane
Proreceptor Arg723 to Ser Absence of proreceptor cleavage [34]
a-subunitb Lys'"" to Glu Absence ofligand dissociation [35]
with acid pH and temperature
a-subunitb Glu"'2 to Stop Premature chain termination
l-subunit Gly996 to Val Decrease autophosphorylation [36]
,B-subunit Trp"" to Ser Decrease autophosphorylation [37]
aCodon sequence per [10]
bCompound heterozygote
mutation in the alpha subunit impairs the translocation ofnewly synthesized receptors
to the plasma membrane, which results in a low concentration of insulin receptors on
the plasma membrane and insulin resistance. The second processing defect involves a
mutation at the cleavage site which inhibits proreceptor processing to the mature
subunits; this defect results in insertion of a low-affinity receptor into the plasma
membrane and insulin resistance.
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